# Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma

Source: https://onco.cc/trials/nct07529782/  
OnCo record `nct07529782` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of Pamlectabart tismanitin run by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., now recruiting.

## Summary

Study to Assess Safety and Efficacy of HDP-101 in Chinese Patients With Relapsed or Refractory Multiple Myeloma is a phase 1 interventional study registered as NCT07529782 by Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd., with 15 participants planned, started 2026-03-17. Conditions recorded: Multiple Myeloma and Other Plasma Cell Neoplasms. Interventions recorded: HDP-101.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07529782
- Phase: 1
- Setting: A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of HDP-101 in Chinese Patients With Plasma Cell Disorders Including Multiple Myeloma
- Sponsor: Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
- Enrolled: 15

## Sources

- ClinicalTrials.gov NCT07529782: https://clinicaltrials.gov/study/NCT07529782

## Connected records

- cancers: [Multiple myeloma](https://onco.cc/cancers/multiple-myeloma/)
- drugs: [Pamlectabart tismanitin](https://onco.cc/drugs/pamlectabart-tismanitin/)
- companies: [Heidelberg Pharma](https://onco.cc/companies/heidelberg-pharma/)

---
JSON: https://onco.cc/api/v1/entities/nct07529782.json